Nanotherapeutics Awarded $20 Million National Institute on Drug Abuse (NIDA)/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents
10/11/2007 9:41:02 AM
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., today announced that it has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA) to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents. Both diseases are highly infectious and could pose a serious danger if used as an aerosolized biological weapon.
comments powered by